Michael Dickinson

University of Melbourne — Australia

Medicine · Health Sciences

44h-index10.5kcitations464works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(219), CAR-T cell therapy research(210), Chronic Lymphocytic Leukemia Research(65), Biosimilars and Bioanalytical Methods(39), Monoclonal and Polyclonal Antibodies Research(31)

Publications461 total

Five-Year Update of the Phase 2 ELARA Trial of Tisagenlecleucel in Patients (pts) with relapsed/refractory Follicular Lymphoma (r/r FL)
Transplantation and Cellular Therapy·2026
The role of neuroimaging in neurotoxicity after chimeric antigen receptor T-cell therapy
Therapeutic Advances in Neurological Disorders·2026Open Access
Supplementary Data Tables from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025Open Access
Supplementary Data Figures from A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development
2025Open Access
Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplemental Figure from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Data1 from A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies
2025Open Access
Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Interview with Beeta Baghoolizadeh
Journal of Global Slavery·2025Open Access
Bispecific antibody combination therapies in diffuse large B‐cell lymphoma
British Journal of Haematology·2025· 1 cited
Antibody-Drug Conjugates and Bispecific Antibodies for Lymphoma: Partners of Convenience or a Perfect Match
Journal of Clinical Oncology·2025
DLBCL tumor microenvironment archetype and CD4+ T cell conversion to cytotoxic cells are required for response to glofitamab
Blood·2025Open Access
Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma
Blood·2025Open Access
A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)
Blood·2025
Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Blood·2025Open Access
page 1 of 24Next →

Frequent Co-authors

H. Miles Prince(13), David Ritchie(8), Anna Sureda(7), Peter A. Riedell(7), Franck Morschhauser(7), David Westerman(7), John F. Seymour(7), Marie José Kersten(6), Joseph P. McGuirk(6), Emmanuel Bachy(6), Fritz Offner(6), Joaquín Martínez‐López(6), Catherine Thiéblemont(6), Constantine S. Tam(6), Olalekan O. Oluwole(5), Chan Y. Cheah(5), Simon J. Harrison(5), Caron A. Jacobson(4), Armin Ghobadi(4), Ian W. Flinn(4)